CIK 0000200406 · Large accelerated filer
JOHNSON & JOHNSON
Sign in to watch- Ticker
- JNJ
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Jan 3
- Incorporated
- NJ
- Entity type
- operating
- EIN
- 221024240
- Phone
- 732-524-2455
- Business address
- ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK, NJ, 08933
- Former names
- JOHNSON & JOHNSON ET AL
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $16,898,386
- in 3 filings
Net −$16,898,386. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-06 | Forminard Elizabeth EVP, Chief Legal Officer | Sale | −9,344 | $257.76 | $2.4M | 23,568 |
| 2026-08-06 | Forminard Elizabeth EVP, Chief Legal Officer | Sale | −6,574 | $255.93 | $1.7M | 16,994 |
| 2026-08-06 | Forminard Elizabeth EVP, Chief Legal Officer | Option exercise · Employee Stock Options (Right to Buy) | −9,344 | 0 | ||
| 2026-08-05 | Duato Joaquin CEO and Chairman of the Board | Sale | −41,957 | $258.06 | $10.8M | 282,490 |
| 2026-08-05 | Duato Joaquin CEO and Chairman of the Board | Sale | −6,523 | $258.74 | $1.7M | 275,967 |
| 2026-07-20 | Broadhurst Vanessa EVP, Global Corp Affairs | Option exercise | +11,129 | $129.51 | $1.4M | 34,132 |
| 2026-07-20 | Broadhurst Vanessa EVP, Global Corp Affairs | Option exercise | +11,925 | $131.94 | $1.6M | 46,057 |
| 2026-07-20 | Broadhurst Vanessa EVP, Global Corp Affairs | Sale | −23,054 | $251.27 | $5.8M | 23,003 |
| 2026-07-20 | Broadhurst Vanessa EVP, Global Corp Affairs | Option exercise · Employee Stock Options (Right to Buy) | −11,129 | 0 | ||
| 2026-07-20 | Broadhurst Vanessa EVP, Global Corp Affairs | Option exercise · Employee Stock Options (Right to Buy) | −11,925 | 0 | ||
| 2026-06-11 | Wengel Kathryn E EVP, Chief TO and Risk Officer | Option exercise | +10,000 | $115.67 | $1.2M | 124,287.87 |
| 2026-06-11 | Wengel Kathryn E EVP, Chief TO and Risk Officer | Sale | −10,000 | $241.15 | $2.4M | 114,287.87 |
| 2026-06-11 | Wengel Kathryn E EVP, Chief TO and Risk Officer | Option exercise · Employee Stock Options (Right to Buy) | −10,000 | 32,965 | ||
| 2026-06-09 | Woods Eugene A. Director | Grant or award · Deferred Share Units | +161.09 | $232.79 | $37K | 6,411.96 |
| 2026-06-09 | Pinto Daniel E Director | Grant or award · Deferred Share Units | +134.24 | $232.79 | $31K | 2,320.82 |
| 2026-06-09 | HEWSON MARILLYN A Director | Grant or award · Deferred Share Units | +214.79 | $232.79 | $50K | 15,791.88 |
| 2026-05-01 | REED JOHN C EVP, Innovative Medicine, R&D | Option exercise | +25,255 | 35,913 | ||
| 2026-05-01 | REED JOHN C EVP, Innovative Medicine, R&D | Shares withheld for taxes | −11,002 | $229.85 | $2.5M | 24,911 |
| 2026-05-01 | REED JOHN C EVP, Innovative Medicine, R&D | Option exercise · Restricted Share Units | −25,255 | 0 | ||
| 2026-04-23 | Woods Eugene A. Director | Grant or award · Deferred Share Units | +975 | 6,215.09 |
Page 2 of 19 · 365 trades